FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (Q38856068)

7 September 2017

title

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (English)

1 reference

chronic obstructive pulmonary disease

7 September 2017

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Helen Barnacle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ruby Birk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Noushin Brealey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Nicholas Locantore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

David A Lomas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Andrea Ludwig-Sengpiel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Rajat Mohindra

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Maggie Tabberer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Chang-Qing Zhu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Steven J Pascoe

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

4 April 2017

1 reference

American Journal of Respiratory and Critical Care Medicine

7 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

438-446

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

Treatment evolution after COPD diagnosis in the UK primary care setting

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Initiation of triple therapy maintenance treatment among patients with COPD in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Device errors in asthma and COPD: systematic literature review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

Risk factors for inadequate use of pressurized aerosol inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201703-0449OC

10.1164/RCCM.201703-0449OC

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28375647%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference